Drug Profile
Research programme: mTOR protein inhibitors - Pfizer
Alternative Names: WYE-125132Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Wyeth
- Developer Pfizer
- Class Pyrazoles; Pyrimidines
- Mechanism of Action MTOR protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Cancer in USA (PO)
- 01 Sep 2011 Early research is ongoing in US
- 15 Oct 2009 Wyeth has been acquired by Pfizer